Related Experiment Video
Updated: Feb 20, 2026
Author Spotlight: Developing Innovative Therapeutic Strategies for Hemorrhagic Shock Research
Published on: March 22, 2024
Challenges for intraventricular hemorrhage research and emerging therapeutic targets
Thomas Garton1, Ya Hua1, Jianming Xiang1
1a Department of Neurosurgery , University of Michigan , Ann Arbor , MI , USA.
Insights
Intraventricular hemorrhage (IVH) causes significant harm in infants and adults. Preclinical research reveals injury mechanisms and potential treatments, like iron chelation, offering hope for improved outcomes.
Area of Science:
- Neuroscience
- Pediatrics
- Neurology
Background:
- Intraventricular hemorrhage (IVH) presents a critical challenge in both premature infants and adults, marked by high mortality and morbidity.
- Current therapeutic options lack FDA approval for improving neurological outcomes, underscoring the need for novel treatments.
- Understanding secondary injury mechanisms and blood component roles in IVH is crucial for developing effective interventions.
Purpose of the Study:
- To review preclinical research on intraventricular hemorrhage (IVH).
- To highlight potential therapeutic targets and treatments for IVH prevention, acute care, and damage repair.
- To bridge the gap between preclinical findings and clinical application.
Main Methods:
- Comprehensive review of preclinical studies focusing on intraventricular hemorrhage (IVH).
- Analysis of secondary injury mechanisms, including the impact of blood components like hemoglobin, iron, and thrombin.
- Evaluation of emerging therapeutic strategies derived from experimental research.
Main Results:
- Preclinical studies have identified key secondary injury pathways following IVH, involving blood components.
- Therapeutic targets related to hemoglobin, iron, and thrombin show promise in preclinical models.
- Iron chelation therapy (deferoxamine) demonstrates potential based on preclinical data and is under clinical investigation for related conditions.
Conclusions:
- Despite advances in understanding IVH injury mechanisms, clinical translation remains limited.
- Targeting downstream pathways of coagulation and inflammation may yield new therapeutic avenues.
- Iron chelation represents a promising therapeutic strategy for IVH, supported by preclinical evidence.
Introduction:
Intraventricular hemorrhage (IVH) affects both premature infants and adults. In both demographics, it has high mortality and morbidity. There is no FDA approved therapy that improves neurological outcome in either population highlighting the need for additional focus on therapeutic targets and treatments emerging from preclinical studies. Areas covered: IVH induces both initial injury linked to the physical effects of the blood (mass effect) and secondary injury linked to the brain response to the hemorrhage. Preclinical studies have identified multiple secondary injury mechanisms following IVH, and particularly the role of blood components (e.g. hemoglobin, iron, thrombin). This review, with an emphasis on pre-clinical IVH research, highlights therapeutic targets and treatments that may be of use in prevention, acute care, or repair of damage. Expert opinion: An IVH is a potentially devastating event. Progress has been made in elucidating injury mechanisms, but this has still to translate to the clinic. Some pathways involved in injury also have beneficial effects (coagulation cascade/inflammation). A greater understanding of the downstream pathways involved in those pathways may allow therapeutic development. Iron chelation (deferoxamine) is in clinical trial for intracerebral hemorrhage and preclinical data suggest it may be a potential treatment for IVH.
